Pharmaceutical

AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19

PRESS RELEASE AB SCIENCE REPORTS POSTIVE RESULTS OF ITS PHASE 2 STUDY EVALUATING MASITINIB IN COVID-19 Paris, 8 July 2024,…

6 months ago

Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma

Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

6 months ago

Hospital PMI® at 55.8%; June 2024 Hospital ISM® Report On Business®

TEMPE, Ariz., July 5, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in June for the 10th consecutive month…

6 months ago

Cosmo Shareholders Approved All Resolutions Proposed by the Board of Directors at Extraordinary General Meeting

Shareholders approved a dividend distribution of € 2.00 per ordinary share; representing an increase of 90% versus last year Shareholders…

6 months ago

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary…

6 months ago

Updates from NurExone: Growth Conference Presentation and Website Relaunch

TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the…

6 months ago

FSD Pharma Files Amended and Restated Material Change Report

Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) ("FSD Pharma" or…

6 months ago

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer

SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free survival at primary analysis and…

6 months ago

ICPO Foundation partners with Nuclear Medicine Research Infrastructure (NuMeRI) to establish an ICPO Collaborating Center

ICPO Center NuMeRI ICPO Foundation signed the contract with Nuclear Medicine Research Infrastructure (NuMeRI) to establish an ICPO Collaborating Center…

6 months ago

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13)…

6 months ago